Recursion Pharmaceuticals (RXRX) Current Deferred Revenue (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Current Deferred Revenue came in at $32.8 million in Q1 2026, down 17.29% YoY from $39.7 million in Q1 2025, and down 12.79% on a QoQ basis from $37.6 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Current Deferred Revenue (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Current Deferred Revenue data on file, last reported at $32.8 million in Q1 2026.
- Quarterly Current Deferred Revenue fell 17.29% year-over-year to $32.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.8 million (down 17.29% YoY) and the FY2025 annual result came in at $37.6 million, down 39.12% from the prior year.
- Current Deferred Revenue retreated to $32.8 million in Q1 2026, from $37.6 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $73.1 million in Q2 2023 to a low of $32.2 million in Q2 2024.
- A 5-year average of $49.4 million and a median of $47.4 million in 2025 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2022 — Current Deferred Revenue surged 537.81% — and 2024, when it sank 55.95%.
- Tracing RXRX's Current Deferred Revenue over 5 years: stood at $56.7 million in 2022, then sank by 35.79% to $36.4 million in 2023, then soared by 69.57% to $61.8 million in 2024, then plunged by 39.12% to $37.6 million in 2025, then dropped by 12.79% to $32.8 million in 2026.
- The last three Current Deferred Revenue figures came in at $32.8 million (Q1 2026), $37.6 million (Q4 2025), and $47.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.59 Mn |
| Mar 31, 2026 | 32.79 Mn |
| Dec 31, 2025 | 37.61 Mn |
| Sep 30, 2025 | 47.36 Mn |
| Jun 30, 2025 | 39.69 Mn |
| Mar 31, 2025 | 39.65 Mn |
| Dec 31, 2024 | 61.77 Mn |
| Sep 30, 2024 | 49.58 Mn |
| Jun 30, 2024 | 32.20 Mn |
| Mar 31, 2024 | 36.62 Mn |
| Dec 31, 2023 | 36.43 Mn |
| Sep 30, 2023 | 73.00 Mn |
| Jun 30, 2023 | 73.11 Mn |
| Mar 31, 2023 | 57.76 Mn |
| Dec 31, 2022 | 56.73 Mn |
| Sep 30, 2022 | 46.75 Mn |
| Jun 30, 2022 | 63.78 Mn |
| Mar 31, 2022 | 54.25 Mn |
| Dec 31, 2021 | 10.00 Mn |
| Sep 30, 2021 | 10.00 Mn |